Artefact

⚕️[New Artefact Health & Pharmaceuticals REPORT: Revolutionizing Drug Development with AI: The Future of Clinical Trials] 📖 Download the #report here: https://lnkd.in/exNeVvtr This comprehensive guide dives deep into how #AI is transforming the #clinicaltrial landscape—making trials faster, more efficient, and more inclusive. With insights from industry leaders from pharmaceuticals such as Johnson & Johnson, Pfizer, and Servier, and tech partners and startups like Deemea, Elaia, Google, Inato, Klineo, and naaia.ai. This paper is a must-read for #pharma innovators and #healthcare professionals, and more. 🔍 What’s inside? It is composed of 4 main chapters: 1️⃣ [Foreword] AI in Clinical Trials - An ongoing revolution. 2️⃣ Real-world impact – Get a closer look at transformative #AIusecases across the clinical trial value chain: a) Clinical Trial Design AI streamlines trial design by predicting outcomes and optimizing patient eligibility criteria. Tools like AI-powered clinical trial optimization, algorithm-based trial success prediction, and TrialGPT improve decision-making by analyzing historical data.  👉 Brice Miranda, Group Chief Data Officer at Servier: “We firmly believe in the transformation of #research and #clinicaldevelopment through AI, having prioritized 18 R&D thematics with multiple high-potential AI use cases, ranging from target identification to trial design.” b) #PatientRecruitment and Enrollment AI addresses inefficiencies in recruitment, with platforms like inato expanding trial access and enhancing diversity and patient commitment. Predictive algorithms identify ideal sites for underrepresented demographics.   👉 Kourosh Davarpanah, Co-founder & CEO at inato:  "70% of trials are concentrated in just 5% of major hospitals, while 90% of potential sites remain underutilized." c) Execution and Management Advanced tools manage #data from decentralized trials, integrating insights to accelerate conclusions. Natural Language Processing (#NLP) automates reporting, reducing timelines by over 50%.  👉 Luca Mollo, Vice-President, Medical Director France at Pfizer: “It drastically cuts #reportdrafting time from 100 days to as little as 48 by quickly processing data, #automatingtasks, and generating a preliminary draft for submission to regulatory authorities.” 3️⃣ Fueling Innovation: Exploring the expanding ecosystem of AI-driven trials. 👉 “We are moving away from being a reactive #healthcareecosystem to a proactive, almost predictive ecosystem,” says Shweta Maniar, Global Director, Healthcare & Life Sciences at Google. 4️⃣ Challenges Ahead: Overcoming barriers to fully realize AI's potential. 👉 “To unlock AI’s full potential, it will be essential to facilitate access to data to conduct life-saving research while still protecting people’s privacy.” - Elisabetta Gatti - Policy Analyst, EMEA Digital Health Advocacy at Johnson & Johnson

🎄H.AI.PPY HOLIDAYS from the entire Artefact team🎄 As 2024 draws to a close, we want to take a moment to thank you all for your trust and collaboration this year. 🎉 This year marked Artefact’s 10th anniversary, and despite challenging economic times, we are proud to have grown our global client base by over 30%. Together, we’ve helped organizations transform rapidly and enhance their competitiveness through our end-to-end services, spanning #data and #AIstrategy to industry-specific field operations. We also welcomed Effixis, an Artefact Company (Switzerland and Belgium) and Brain Food, an Artefact Company (Chile) into the Artefact family, further expanding our global reach and strengthening our expertise in advanced #AIsolutions. 🌐 At Artefact, we’ve also taken #GenerativeAI from hype to reality, transitioning from proof of concepts to scalable, impactful solutions that deliver measurable results. 🚀 Achieving business value with AI requires focused effort and expertise, and we’re proud to have been a trusted partner on this journey for so many of you. Looking ahead to 2025, we are thrilled to invite you to #AdoptAI2025, our flagship #event taking place on September 17–18 at the iconic Grand Palais - RMN (Officiel) in Paris. ✨ This one-of-a-kind summit will bring together top leaders and innovators to explore how AI can transform industries, drive growth, and unlock new opportunities. From AI for Finance, Healthcare, Tourism, Luxury & Beauty to AI for the Planet, this event will showcase cutting-edge insights and initiatives across industries. 📆 Save the date, we’d love to see you there! 🤝 Thank you for being part of our journey, and we look forward to building even greater success together in 2025. Wishing you a joyful and restful holiday season with your loved ones! 🥳

[Artefact Data & Al Digest - December News | Happy Holidays | Our collection of 2024 reports | #AdoptAISummit - September 17th & 18th, 2025. 👉 Read here: https://lnkd.in/ePPdGAQJ Here is what you’ll learn about in our monthly newsletter: 1️⃣ Happy Holidays from all of us at Artefact! We wish you a joyful holiday season and a fantastic start to 2025, filled with success, innovation, and new opportunities. 🎉 2024 was a milestone year at Artefact as we celebrated 10 years of delivering impactful #dataandAI solutions. From turning #GenerativeAI into real, scalable value to helping organizations transform their operations, we’re excited to continue driving tangible impact together 🎥 Watch our Happy Holiday Video: https://lnkd.in/ebX2dkXi 2️⃣ 📖 Discover our 2024 report collection: https://lnkd.in/efi8VqUh Enjoy reading during the holiday season our white papers: 💊 Revolutionizing Drug Development: https://lnkd.in/exNeVvtr ✨ Data & AI for the Luxury Industry: https://lnkd.in/eGt6hbQw 🏭 IT/OT Convergence - The data dream for industrial excellence: https://lnkd.in/e2CDAWRm 💡 Adopt AI Summit Report: https://lnkd.in/e8yj2CeN 📜 Digital Markets Act (DMA): https://lnkd.in/gySWgk_M 🎯 Unlocking GMP Potential with Artefact: https://lnkd.in/g4DTEGEZ And more… 3️⃣ Save the Dates! 📆 The Adopt AI Summit 2025 will be at Grand Palais, Paris on Sept 17-18 This one-of-a-kind event brings together all major Artefact initiatives AI for Finance, AI for Health, AI for Industry, AI for Sport, AI for Luxury, AI for Tourism, AI for Life, AI for the Planet, offering an unparalleled opportunity to hear from the world’s top thought leaders in AI transformation.. Contact Damien GROMIER, CEO and founder of Adopt AI, to become a sponsor and reserve your exhibition spot. Thank you for being part of our journey. We deeply value our partnership and look forward to building on it further. 🤝 Wishing you a joyful and restful holiday season with your loved ones! Stay informed, stay inspired! 📰 Sign up for our Artefact #Data & #Al Digest newsletter: https://lnkd.in/dbbC-3Jr 

[🎬 Replay of the conference with Servier about accelerating drug innovation through AI at the AI for Health Summit] with Dr. Claude Bertrand, Executive Vice-President R&D at Servier, Virginie Dominguez, Executive Vice-President Digital, Data & IT at Servier, and Paul de Balincourt, Partner at Artefact. 👉 Watch and get inspired by Servier leaders' points of views: https://lnkd.in/eRdZuV6T Servier is a global #pharmaceuticalgroup governed by a Foundation operating in 150 countries. Servier is an independent group that invests over 20% of its brand-name revenue in #ResearchandDevelopment every year. As a world leader in cardiology, Servier aims to continue being an innovative player in oncology, particularly in targeting hard-to-treat cancers, while building a strong neuroscience franchise. Servier is at the forefront of integrating AI to revolutionize #drugdevelopment and #patientcare, aiming to create a more personalized and effective treatment. 🔎 Key insights from the discussion: - Drug discovery is lengthy and complex, 90% of drug candidates fail in clinical development. Servier uses #AI to accelerate #innovation, improving efficiency.  - Servier adopted an opportunistic phase to prove AI’s potential and align teams, followed by a systemic phase embedding AI across R&D. This approach targets 16 critical points of the #druginnovationprocess with 20 high-impact AI initiatives. - AI has significantly improved #targetqualification reducing scientists’ workloads by 90%, leading to higher-quality drug targets. It has also streamlined drug design for small molecules and nucleotide-based therapies. AI also speeds up #patientrecruitment and supports clinical trials design, drastically reducing time and improving decision-making in early-phase trials. - Servier’s co-founded with Oncodesign Precision Medicine a virtual campus initiative, with fostering public-private collaborations. It also relies on external partnerships like Owkin and Aitia. 📖 Read the AI for Health REPORT: https://lnkd.in/g3vV_vW9 📆 Save the dates! We’re excited to announce that AI for Health will return on September 17th-18th, 2025 at the GrandPalaisRmn in Paris, as part of the major #AdoptAISummit by Artefact. Get ready for an even bigger and bolder celebration of innovation for health! ✨

[Don't miss this live Streaming Interview, today at 6 pm CEST 🚨 Forecasting with AI in the #FinancialServicesIndustry: a real use case] 💡 Nicolas Boucher, Founder of the AI Finance Club, will be interviewing Florent Bernard, Partner at Artefact on maximizing the #powerofAI to leverage advanced algorithms and vast amounts of data to deliver accurate, actionable predictions. 📆 Today! 🕰️ 12 pm ET / 9 am PT / 6 pm CEST 👉 There's still time to register: https://lu.ma/tv6ykl2j 🎤 Nicolas Boucher is the famous founder of the AI Finance Club, the place where #financeprofessionals learn and stay up to date on how to use #AIinFinance. 1,5 million professionals are following his daily insights on Finance and AI. Nicolas already trained over 5,000 finance pros and over 80 companies on AI for Finance. Join his AI for Finance Club, as a member, you’ll get access to live workshops, masterclasses, and AI courses in Finance, and get exclusive content such as newsletters: https://ai-finance.club/ 🎤 Florent Bernard is a Consulting Partner at Artefact, where he leverages his extensive expertise to drive data and #AItransformations for global organizations. With an INSEAD degree and a career spanning over 20 years, Florent has held pivotal roles across consulting, technology, and finance, enabling him to bring a multidisciplinary perspective to complex challenges. Before joining Artefact, Florent served as an Associate Partner at McKinsey & Company and he also began his career at BNP Paribas Securities Services, holding roles as a Performance & Risk Analyst and Assistant Fund Manager, focusing on quantitative research and risk analysis. 🔎 You can join this live streaming interview that will be focusing on a real use case: - Why do you need #AIforForecasting - Real #usecase demonstration - Which data do you need - Future of AI in #FSI Florent will share his experience from the field, and explain how he delivers end-to-end solutions, from #datastrategy & governance to operations, implementing #AIprojects at scale. Don't miss this opportunity to elevate your #forecastingstrategies with AI. 🚀

[📄 Revolutionizing Policy Drafting with Generative AI] In this new article, Hamza Halabi, Senior Data Scientist at Artefact MENA, shares an insightful case study on how #generativeAI is transforming the #policydraftingprocess. ➡️ Check out the full article here: https://lnkd.in/dhSxVtdw Traditionally, creating and maintaining policies was a manual, time-consuming task fraught with inefficiencies. But with the power of #AI, we’re changing the game. 🚀 💡 Hamza and the team developed an innovative web application that combines OpenAI’s GPT-4o and custom #AItools to automate two critical phases: - Automated web research: Conducting real-time, parallel searches to gather policy content and perform comparative analysis in under 5 minutes. - AI-driven policy drafting: Generating fully structured policy drafts in real-time, ensuring accuracy and consistency. 🔑 The results: Time spent on #policydrafting has been slashed by over 50%, with key tasks now taking only half the time they did previously. This solution is not only more efficient but ensures better consistency and accuracy, empowering organizations to focus on higher-value tasks.

[🎬 Artefact at ai-Pulse 2024, organized by Scaleway at Station F, in Paris] Watch the #replay of the discussion panel featuring Fabrice le Chatelier, Head of Data Science Office at BNP Paribas, Hanan OUAZAN, Partner at Artefact, and ioan iacob, CEO & Founder at FlowX.AI. 👉 Download the replay of the discussion on AI’s role in #FinancialServices: https://lnkd.in/edngQgyu Discover the key insights from the roundtable! 🔒 #AI & #data privacy: Fabrice Le Chatelier shares how the bank balances #AIinnovation with strict #dataprivacy standards, ensuring compliance while leveraging AI for better business outcomes. 🤝 Collaborative AI development: Successful #AIimplementation requires strong collaboration among IT teams, data scientists, and business units. BNP Paribas demonstrates this approach by distinguishing between strategic #AIprojects developed in-house and standardized solutions sourced from external vendors. ⚙️ #HybridAImodels & legacy systems: Artefact implemented a hybrid AI solution to improve email routing at BNP Paribas, combining traditional #NLP and large language models (#LLMs). This solution achieved a 24% reduction in email routing errors through #AIdrivenautomation, saved significant time (which represents ~14 years in total per year), and boosted advisor productivity with 80% accurate response suggestions. 🎯 AI accuracy & #security: FlowX.AI discusses its approach to minimizing risks and boosting the accuracy and security of AI models in financial services. The speakers emphasized the importance of building robust AI models that can seamlessly integrate with existing infrastructure, driving both operational efficiency and customer satisfaction. You can also download Scaleway’s #aiPULSE 2024 Whitepaper and unlock key insights: https://lnkd.in/evCPiyyE  

[📖 Read the report about the conferences of  the AI for Health Summit 2024 and watch all the replays] If you could not attend this international event last November, founded by Artefact and Johnson & Johnson, benefit in this eBook of videos and summaries of the main keynotes and discussion panels of world-class speakers. 👉 Download the Report of the #AIforHealthSummit with Replays & Syntheses: https://lnkd.in/g3vV_vW9 👏 Our lineup of business and technology leaders:  - 145+ high-level speakers from the major actors of the Pharma and Health sector made us the honour of sharing their return of experience: Pfizer, Servier, Biogen, Roche, Novo Nordisk, Takeda, Amgen, Clariane, French Ministry of Health (G_NIUS), Healthcare Data Institute, EIT Health, PariSanté Campus, Resah, Unicancer… - Our Technology Partners: Amazon Web Services (AWS), InstaDeep, IQVIA France, Microsoft, MyData-TRUST - Data Protection & Privacy for Life Sciences, Nebius, Pure Storage, Salesforce, Sqilline Health, Theodo HealthTech (ex-Hokla), TriNetX, VIDAL… 🚀 This #report is full of invaluable insights, strategic advice and use cases to help you make decisions for a positive and efficient #transformation of your enterprise within the healthcare and pharmaceutical area through the power of #data, #AI and generative AI. 📆 Save the dates! We’re excited to announce that AI for Health will return on September 17th-18th, 2025 at the GrandPalaisRmn in Paris, as part of the major Adopt AI Summit by Artefact. Get ready for an even bigger and bolder celebration of innovation for health! ✨

🎤 Entretien The Bridge by Artefact, en vidéo et podcast, sur la transformation data & IA dans l’#industriedelasanté avec Justine Nerce, Managing Partner Artefact France et Global Lead #Healthcare. 📽️ Regardez l’interview de Justine par Caroline Goulard, CEO de Dataveyes et Modality : https://lnkd.in/e_SWWAgr 🎧 Ecoutez le podcast : https://lnkd.in/eBzBsq2w 🔎 Justine explique comment l’#IA permet de répondre aux enjeux auxquels les #entreprisespharmaceutiques, les #laboratoiresderecherche et les #institutionshospitalières sont confrontés :  1- L'accélération de l'accès au marché et la maîtrise des coûts de la R&D, 2- La lutte contre les ruptures de médicaments, 3- L’égalité de l’#accèsauxsoins Justine est au cœur de la création de la #PratiqueSanté, qui compte 100+ experts, avec une croissance annuelle >50 %, et collabore avec 30+ clients, couvrant un large éventail de #solutionsIA, allant de l’optimisation de la R&D pharmaceutique, en passant par l’amélioration des #parcoursdesoins, jusqu'à l’amélioration des chaînes d'approvisionnement, et plus encore ! 💡 Justine partage des cas d’usage IA innovants : ⚕️ Cas n°1 - Accélérer le développement de nouveaux traitements L’innovation thérapeutique est un processus complexe et coûteux. Avec des brevets valables 20 ans, le Time To Market est crucial pour rentabiliser un médicament. > Qualification des cibles : centralisation et exploitation d'informations dans des outils dédiés, tableaux de bord avancés en temps réel pour une aide à la décision optimisée. > Essais cliniques : génération automatique ultra rapide de documents, tels que des brochures à destination des médecins ou la rédaction de protocoles cliniques. > Accès au marché facilité : des outils d'IA qui génèrent et synthétisent des documents critiques pour les demandes d'Autorisation de Mise sur le Marché. 💊 Cas n°2 - Réduire les ruptures de médicaments. > Les données offrent une meilleure visibilité sur les stocks et la traçabilité. > L'IA optimise la prévision de la demande et améliore la prise de décision en temps réel. > La maintenance prédictive peut être améliorée grâce aux données des capteurs IoT. > Des scénarios de mitigation en cas de perturbation réduisent risques et gaspillage. 🩺 Cas n°3 - Démocratiser l'accès aux soins grâce aux données. Le manque d'accès aux données médicales met à mal la fiabilité des diagnostics et le traitement de certaines maladies. > Identification des zones en difficulté via des données réelles. Résultats attendus : réduction des disparités, meilleure information pour les médecins et réallocation des ressources. > Utilisation du Machine Learning en fournissant aux équipes de vente un assistant capable de gérer une grande quantité d'informations complexes. Elles optimisent leurs décisions grâce à des systèmes qui personnalisent les interactions avec les professionnels de santé (HCP).

🌟 Artefact Acquires Brain Food, an Artefact Company to Strengthen Its Leadership in Latin America’s Data & AI Consulting Market and Boost #GlobalExpansion. We are delighted to announce that Artefact has acquired Brain Food, a thriving Chilean consulting firm specializing in #data, #analytics, and #AI services. 🇨🇱 This strategic partnership is a major milestone in our journey to expand within the growing #LatinAmericanmarket and reinforces Artefact’s commitment to #globalleadership in data and AI consulting. 👉 Read the press release: https://lnkd.in/gYwcGSMp   Founded in 2015 by visionary leaders David Albagli and Andres Oksenberg, Brain Food has achieved remarkable growth, 📈 delivering #transformativeprojects for leading companies across Latin America, including Visa, Aeromexico, Femsa, Nestlé, and Seguros Pacífico. "This partnership marks an exciting chapter for Brain Food," said David Albagli, founder & CEO of Brain Food. “We see ourselves reflected in Artefact’s mission and are eager to scale our impact, delivering even greater value to our clients with their global support. 🌐 Artefact’s #internationalleadership in data and AI consulting opens new opportunities for #innovation and growth while allowing us to stay deeply connected to our Latin American roots.” 🤝 "We’re thrilled to partner with Artefact, whose vision and approach closely mirror our own," added Andres Oksenberg, Partner at Brain Food. "Like Artefact, we prioritize a collaborative yet rigorous culture, where people can thrive, develop their skills, and maintain a healthy work-life balance—a key factor in our decision to join forces." By joining forces, Artefact and Brain Food bring together complementary expertise and a shared DNA in #datadriventransformation.💡We’ll continue to bridge the gap between data, #technology, and business, empowering clients across industries to unlock their full potential. André Bebber da Fonseca, Managing Partner of Artefact LATAM, who has been instrumental in Artefact’s development across the continent, commented: "This acquisition builds on our recent successes in the region, including sixfold growth in Brazil since 2021 and the opening of offices in Colombia and Mexico last year. Brain Food’s dynamic team and strong #clientrelationships make them the perfect partner to fuel our growth in new markets across the region." Vincent LucIAni, CEO of Artefact, concluded: "Latin America’s demand for #datatransformation is accelerating, and Brain Food’s leadership and high-impact culture align perfectly with our vision. Together, we will continue to invest in expanding our reach across the continent, with the goal of more than doubling in size organically over the next 3 years." We’re thrilled to welcome David, Andres, and their incredible team of 60+ professionals to Artefact. Their talent and commitment to innovation will play a key role in shaping Artefact’s bright future as we move toward 2025 and beyond. 🚀